Bridging the gap in nanoparticle based enzyme biosensing
There is growing commercial interest in bio-responsive materials because of their many applications, such as in medical
diagnostics at the point of care and in drug discovery and development. Our developed assay technologies manip...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-119087RB-I00
TEST RAPIDOS BASADOS EN NANOMATERIALES PARA DETERMINACION DE...
198K€
Cerrado
PID2020-113081RB-I00
BIOMATERIALES EN NANOINGENIERIA: PRODUCCION Y APLICACIONES E...
169K€
Cerrado
PCI2019-103715
NANOPARTICULAS MAGNETICAS AVANZAS PARA DETECCION Y CUANTIFIC...
59K€
Cerrado
PCI2019-103600
NANOPARTICULAS MAGNETICAS AVANZAS PARA DETECCION Y CUANTIFIC...
145K€
Cerrado
BARCODE DIAGNOSTICS
Next Generation Personalized Diagnostic Nanotechnologies for...
1M€
Cerrado
TwistedNano
Twisted nanophotonic technology for integrated chiroptical s...
4M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
There is growing commercial interest in bio-responsive materials because of their many applications, such as in medical
diagnostics at the point of care and in drug discovery and development. Our developed assay technologies manipulate
the properties of gold nanoparticles and enzyme-based reactions to detect enzyme activity. Most diagnostics target either
expressed antigens (immunodiagnostics) or DNA (molecular diagnostics).
Our bio-responsive nanoparticle technology can offer a sensitive, specific and affordable platform for the development of rapid
point-of-care tests based on simple colour readouts. Additionally one of the great advantages of our technology is the fact
that, in addition to diagnosing disease, it can also potentially help in the search for new drugs to treat those diseases. In
contrast to methods that simply measure enzyme concentration, our method actually measures enzyme activity. In this ERC
POC our expected outcomes include a number of important commercial milestones and technical developments to expand
the platform to other diseases and test its application in high throughput drug screening. This value
will carry through in both licensing and spin-out, since these issues are fundamental to any business venture. Furthermore,
we propose a balanced plan that includes technical research combined with commercial investigations and identification
of appropriate industrial partners. At the conclusion of this work, we will be in a much stronger position to immediately
commercialise this technology, bringing its benefits to the broader healthcare market.